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Abstract
During the last decades efforts regarding dietary iron
supply focused mostly on the prevention of deficiencies,
especially during growth and pregnancy. Correspond-
ingly, homeostatic mechanisms increase intestinal iron
absorption in iron deficiency, but its downregulation at
high intake levels seems insufficient to prevent accumu-
lation of high iron stores at high intake. There is no regu-
lated iron excretion in overload. Excess of pharmaceuti-
cal iron may cause toxicity and therapeutic doses may
cause gastrointestinal side effects. Chronic iron excess,
e.g. in primary and secondary hemochromatosis, may
lead to hepatic fibrosis, diabetes mellitus and cardiac
failure. Chronic intake of 50–100 mg Fe/day of highly
bioavailable iron with home-brewed beer in sub-Saha-
ran Africans lead to cirrhosis and diabetes. Applying a
safety factor of 2 would lead to an upper safe level of
25–50 mg Fe/day for this endpoint of conventional iron
toxicity. However, beyond this kind of damage iron is
known to catalyze the generation of hydroxyl radicals
from superoxide anions and to increase oxidative stress
which, in turn, increases free iron concentration. This
self-amplifying process may cause damage to lipid
membranes and proteins, which relates radical genera-
tion and organ damage after ischemia-reperfusion
events to available free iron in clinical and experimental
settings. Correspondingly, epidemiological studies as
well as observations in heterozygotes for hereditary he-
mochromatosis suggest that the risk of atherosclerosis
and acute myocardial infarction is related to body iron
stores, though there is conflicting epidemiological evi-
dence as well. The most recent and best controlled stud-
ies, however, support the hypothesis that iron stores are
related to cardiovascular risk. Iron-amplified oxidative
stress may also increase DNA damage, oxidative activa-
tion of precancerogens and support tumor cell growth.
This is supported by experimental, clinical and epidemi-
ological observations. Due to these mechanisms high
iron stores may present a health hazard. Though this has
not been finally proven, available evidence strongly rec-
ommends not to increase iron intake beyond physiologi-
cal requirements. To avoid iron deficiency symptoms, on
the other hand, care must be taken to meet recom-
mended daily intake.
Copyright © 2001 S. Karger AG, Basel
Introduction
The efforts of the evolution to avoid the hazards of
micronutrient deficiency and excess are shared by corre-
sponding regulatory efforts. The ‘recommended dietary
allowance’ (RDA) is supposed to meet the nutritional re-
quirement of 97.5% of the healthy population. For certain
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micronutrients beneficial health effects are observed at
intake levels that exceed requirement extensively. For
example, selenium and vitamin E seem to counteract free
radical damage. Thus, to optimize health it may be desir-
able to consume such micronutrients in excess of the
RDA. This development urges regulatory agencies to
establish an ‘upper level’ (UL) to mark the borderline
between favorable health effects and toxicity. The first
step in this process is hazard identification, i.e. to spot
adverse effects that may lead to persistent impairment of
important physiological functions. The next step is to
derive a dose-response relationship for such adverse ef-
fects and to estimate a ‘no adverse effect level’ (NOAEL)
or a ‘lowest adverse effect level’ (LOAEL) from available
data. An UL can be derived on this basis by use of appro-
priate safety factors and uncertainty factors. These factors
make provisions for sensitive subpopulations and for
doubts regarding the reliability of available data [1].
Dose-response assessments for iron present several
problems. Firstly, bioavailability of nonheme iron varies
by a factor of 10, depending on the composition of the diet
[2]. In addition, heme iron absorption is substantially
higher than that of nonheme iron. It contributes 20–35%
to total iron intake [3] corresponding to 1–5 mg Fe/day,
which is a considerable range of variation. Due to these
uncertainties, it is difficult to assess absorbed iron quanti-
tites at known intake levels. This problem is circum-
vented by relating the endpoints of iron toxicity to the
iron status of the organism.
Rationale behind RDAs and Corresponding
Recommendations of the Deutsche
Gesellschaft für Ernährung for Dietary Iron
Intake
Iron deficiency anemia affects an estimated 25% of
infants worldwide and up to 46% of children 18 months
of age in Guatemala [4]. Children with iron deficiency
anemia run a higher risk of an insufficient psychomotor
development and impaired cognitive performance [5].
Reduced O2 supply and cytochrome activity lead to
reduced physical performance and low birth weight ba-
bies [6]. Therefore, the RDA should be high enough to
replace the body’s iron losses and to fulfil physiological
requirements, especially during growth and pregnancy.
A 70 kg male loses approximately 1 mg Fe/day with
desquamated epithelial cells. Assuming a 10% absorption
rate, an intake of approximately 10 mg Fe is needed to
replace these basal losses. Menstrual iron losses are below
1.6 mg Fe/day in 95% of women. Added to basal losses
this leads to an average total loss of approximately 2.5 mg
Fe/day [6]. Assuming an absorption rate of 10–20% in
iron deficiency, an RDA of 15 mg Fe/day for women of
reproductive age is derived. During the 1st year of life the
body requires approximately 260 mg of iron for metabo-
lism and growth, i.e. 0.6–0.8 mg Fe/day, corresponding to
a dietary intake of 6–8 mg Fe/day per infant. This is the
rationale for the RDA value of 1 mg Fe/kg body weight for
children between the 4th month and 3rd year of life. A
total intake of 15 mg Fe/day is not to be exceeded in
infants. During pregnancy, 450 mg Fe are needed for the
mother’s increased erythropoiesis, 270–300 and 50–
90 mg are transferred to fetus and placenta, respectively,
amounting to an extra demand of 770–840 mg. This
demand corresponds to approximately 3 mg Fe/day and
to an intake of 30 mg Fe/day which is the rationale for the
recommended higher iron intake in pregnancy. It may be
a problem for risk management when it comes to avoid
iron overload for those segments of the population with
low iron requirements and, at the same time, to supply
enough iron to those with a high demand. In the USA,
RDAs are exceeded by actual dietary iron intake in males
and they are nearly met in females; the prevalence of iron
deficiency anemia is as low as 2.5–4.0%. These data show
that the RDAs and corresponding recommendations of
the DFG are solidly based and that iron deficiency in
industrialized countries has become less of a general
health problem. This is in part due to a diet favorable for
iron bioavailability and partly to the mechanisms of iron
homeostasis.
Regulation of Intestinal Iron Absorption
Depending on its weight the iron-adequate human
body contains 2.2–3.8 g of iron (distribution see table 1)
[7]. Intestinal iron absorption is geared to the demand via
adaptation of a specific receptor population in the duode-
nal brush border membrane (BBM) [8]. The iron supply
from the blood to the immature enterocytes in the duode-
nal crypts modulates cellular iron-regulating protein
(IRP) activity (details see below) which, in turn, seems to
regulate the expression of a divalent metal transporter
(DMT-1) in the BBM. This process gears nonheme iron
uptake from the intestinal lumen to the body’s iron
requirements [9]. A second mechanism seems to modu-
late the function of DMT-1 in the BBM and the disloca-
tion of this carrier from the membrane in response to
recent iron absorption, which corresponds to a mucosal
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block [10]. Duodenal nonheme iron absorption is further
modulated by the iron-regulated transporter at the baso-
lateral membrane of duodenal enterocytes (IREG) [11].
Body iron stores also influence the expression of a BBM
reductase that reduces ferric food iron to the ferrous form
to make it available to DMT-1. Heme iron, in contrast, is
not taken up via DMT-1 but passes the BBM as an Fe-
porphyrin complex [12] either by virtue of its lipophilicity
or by use of a putative heme carrier. Heme iron, thus, cir-
cumvents downregulation of the bottle neck for nonheme
iron absorption in iron overload. The porphyrin ring is
cleaved by heme oxygenase in the enterocytes [13]. The
released iron enters the enterocytes’ nonheme iron pool.
Although there is some adaptation of heme binding to the
BBM [14] and of heme oxygenase activity, downregula-
tion of heme iron absorption at adequate supply levels is
by far not as effective as that of nonheme iron absorption
[15].
In humans, nonheme iron absorption from food in-
creases markedly in a situation of increased demand. A 4-
and 9-fold increase was found in blood donors and in
pregnant women, respectively [15, 16]. When iron stores
are repleted, noheme iron absorption goes down and bal-
ances basal iron losses at normal dietary intakes [15].
However, although the percentage of iron absorption
decreases, administration of high amounts of iron inevita-
bly results in the absorption of higher amounts of iron
[17]. Especially, downregulation of intestinal iron absorp-
tion in response to preceding iron administration [muco-
sal block; 10] does not seem to work effectively in
humans. Thus, increases in plasma iron concentrations
after oral intake of 75 mg Fe were similar to the increase
after a second and third dose given on the same day [18].
When iron was given with the meal – corresponding to the
situation of food fortification – 2.6% (1.3 mg Fe) were
absorbed from a single dose of 50 mg FeSO4. When 50 mg
Fe/day were given for a week (350 mg Fe), absorption was
2.3% (8.0 mg Fe), showing no blocking effect of preceding
iron doses [19]. Also, the absorption rate (8.9%) after
60 mg Fe/day for 6 days (total intake 360 mg Fe) was in
the same order of magnitude as after intake of 120 mg Fe
once weekly for 3 weeks (10.9%) [20]. When nonheme
iron absorption was as low as 2%, heme iron absorption
was still as high as 15% [15] showing that downregulation
of heme iron absorption in response to increasing iron
stores is even less effective than that of nonheme iron in
humans. Iron excretion is not regulated. At normal intake
levels about 1 mg Fe/day is lost with the desquamated
enterocytes, corresponding to as little as 0.025–0.05% of
body iron content. The examples show that downregula-
Table 1. Distribution of body iron content [data taken from 7]
Males
mg mg/kg BW
Females
mg mg/kg BW
Functional iron
Hemoglobin 2,300 31 1,700 28
Myoglobin 320 4 180 3
Heme enzymes 80 1 60 1
Nonheme enzymes 100 1 76 1
Iron stores
Ferritin 700 9 205 3
Hemosiderin 300 4 90 1
Total 3,800 50 2,200 37
tion of intestinal iron absorption may not be sufficient to
protect from iron overload and that dietary intake levels
have to be adapted accordingly. Moreover, adaptation of
intestinal iron absorption works to an even smaller extent
in heterozygotes for hereditary hemochromatosis [21],
who make up approximately 10% of the population of
North-European origin.
High iron contents in the diet will decrease Zn absorp-
tion which, however, needs pharmaceutical iron doses
[22]. The iron impact on Cu absorption is even less pro-
nounced.
Iron Homeostasis
Excess iron is sequestered into ferritin, from where it
can be mobilized when demand increases. A small family
of messenger RNAs is equipped with specific base loops
(iron-responsive element, IRE) that bind to IRP in the
cytosol. Binding of IRP to the IRE in the 5) untranslated
region (UTR) of the mRNA represses ferritin translation;
binding to multiple IREs in the 3) UTR, in contrast, stabi-
lizes the mRNA of the transferrin receptor. The IRP-IRE
affinity is increased in iron-deficient cells (fig. 1). This
mechanism modulates the expression of ferritin and
transferrin receptors and, thus, regulates the availability
of low molecular iron in the cells [23]. Unfortunately, the
same mechanism will also mobilize iron from ferritin and
import it via transferrin receptors in situations of oxida-
tive stress. Nitric oxide and superoxide radicals increase
the IRP-IRE affinity [24]. Thus, cells under oxidative
stress are likely to behave as in iron deficiency: they can
release iron from the stores and increase iron uptake from
the extracellular space (fig. 1). This misguided process
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Fig. 1. Function of the IRP 1. IRP-1 is a bifunctional cytoplasmic
protein with a molecular mass of 98 kD. In iron-deficient cells the
protein loses a cuban 4Fe-4S cluster and a wide cleft forms between
the domains 1–3 and domain 4. This apoprotein binds to IREs which
are specific base loops at the 3) UTR of the transferrin receptor
mRNA and at the 5) UTR, e.g. of the ferritin mRNA. IRP-binding
stabilizes the transferrin receptor mRNA which increases transferrin
receptor expression and cellular iron import. Binding to the IREs at
the 5) UTR destabilizes the ferritin mRNA and decreases cellular
iron sequestration. Both events should increase free iron in the cyto-
sol, leading to new cluster formation in the IRP and a narrow cleft. In
this situation the protein shows aconitase activity and does not bind
to IREs. An ‘opened’ conformation with sufficient space in the cleft is
also observed at high NO and H2O2 concentrations. C437 appears to
be the critical cysteine residue which accounts for the sensitivity of
IRP-1 to redox manipulation [taken from 89].
may amplify oxidative stress. Besides, homeostasis can be
overwhelmed by excess iron intake. In all these situations,
iron may cause substantial harm to the body, depending
on dose and duration of excess iron exposure.
Damage after Acute Iron Exposure
Ingestion of an acute overdose of pharmaceutical iron
preparations is known to cause local corrosion in the
stomach and upper small intestine. High absorbed iron
quantities cause shock symptoms due to postarteriolar
dilatation, capillary leakage and heart failure. High iron
concentrations damage hepatic mitochondria, leading to
liver cell necrosis with bleeding disorders and hepatic fail-
ure. Though the mortality rate from iron intoxication
increased from 0.05 before 1990 to 0.116 per 100 patients
exposed to iron preparations in 1991 [25], it is overall a
rare event. An oral dose of 180–300 mg Fe/kg body weight
can be lethal. Oral doses below 10–20 mg Fe/kg body
weight are regarded as nontoxic for humans [26], leading
to a NOAEL of 10 mg Fe/kg body weight for acute iron
toxicity. This is far beyond the dose range of dietary iron
exposure.
At therapeutic dose levels a series of side effects of oral
iron preparations due to irritation of the gastrointestinal
mucosa were observed, including nausea, vomiting, heart-
burn and epigastric discomfort. Along with diarrhea and
obstipation, these side effects were observed in about 25%
of patients after administration of 100 mg Fe/day in a pla-
cebo-controlled study [27]. An earlier study found the
same side effects at 180 mg/day. If 100 mg Fe/day is taken
as LOAEL, a safety factor of 2 leads to an USL of 50 mg
Fe/day for mucosal irritation by nonheme iron salts. Red-
dajah et al. [28] described gastrointestinal side effects at
doses of 50 mg Fe/day in non-placebo-controlled study.
Thus, the USL for this effect should be below 50 mg Fe/
day, e.g. 30–40 mg Fe/day. One has to consider, though,
that the ‘daily intake’ was taken as a single dose of iron
salt in these studies. This is different from dietary intake
and limits the value of these data for extrapolation to food
iron.
Chronic Iron Overload
Hazards can also be identified for excessive chronic
iron ingestion. Symptoms such as hepatomegaly, joint
inflammation, diabetes mellitus, cardiac failure or hepa-
toma are possible sequels of parenchymal iron overload.
Excess iron is a major factor in the progression of hepatic
fibrosis at concentrations above 400 Ìmol Fe/g dry
weight. Patients who ingested 160–1,200 mg/day phar-
maceutical iron over more than a decade developed sec-
ondary hemochromatosis and died of cirrhosis, diabetes
or cardiac failure [29]. Such cases are inappropriate to
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derive a LOAEL or NOAEL, as they deal with excessively
high intakes and did not exclude hereditary hemochroma-
tosis.
Homozygotes for hereditary hemochromatosis are a
highly sensitive subpopulation for iron overload. This dis-
ease is caused by a defect in the HLA (HFE) gene which
increases iron absorption 2- to 3-fold. It is observed in
0.3–0.5% of the Caucasian population. The male/female
ratio among homozygotes is 1:1; for serious manifesta-
tions it is about 5:1, though, if untreated. This is because
women have constantly higher iron losses via menstrual
bleeding. In hereditary hemochromatosis, transferrin sat-
uration is frequently close to 100%. Free, bleomycin-
detectable iron is often present and parenchymal cells can
be damaged, e.g. by Fenton chemistry.
Bantu siderosis is caused by excess oral iron intake
with home-brewed beer, fermented in iron drums in sub-
Saharan Africa. Regular consumption of such beer may
serve as a model for chronic dietary iron overload, leading
to hepatic cirrhosis and diabetes. The bioavailability of
such iron is high. It parallels that of FeCl3 salts and is
approximately one third of that of Fe2+ salts. The average
intake in the patients was 50–100 mg Fe/day [30]. A
cumulative excess intake of approximately 28 g Fe was
derived as a threshold for the development of fibrosis.
The average consumption seems to have been less than 2
liters of beer/day which is too little for clear-cut alcohol-
ism. Still, substantial alcohol intake in some patients
might have supported the development of cirrhosis. Iron
absorption in cirrhotic subjects was not higher than in
healthy controls [30], although a genetic failure distinct
from HLA-linked hemochromatosis was later discussed
to have increased intestinal iron absorption [31]. These
findings lead to a LOAEL of 50–100 mg Fe to cause cir-
rhosis in the long run. Applying a safety factor of 2 seems
sufficiently conservative, because we deal with a putative-
ly sensitive subpopulation, for which a genetic disposition
and alcohol intake are discussed. Therefore, a USL of 25–
50 mg Fe/day should be derived from these data.
Iron, Increased Oxidative Damage and
Cardiovascular Risk
In 1992 Salonen found marginally increased iron
stores to be related to an excess risk of acute myocardial
infarction (AMI). These data supported Sullivan’s iron
hypothesis [32] on the increased cardiovascular risk from
1981 which was based on three observations. (1) In paral-
lel to higher iron stores, men have a higher risk of AMI
Fig. 2. Impact of iron on the metabolism of active oxygen species.
Active oxygen species (O2–W and H2O2) lead to the mobilization of
stored iron, to lipid peroxidation and to cell injury and death. The
antioxidant enzymes and vitamins (shown in italics) and their points
of intervention in the process are indicated by dotted lines [taken
from 35].
than premenopausal women, (2) hysterectomized women
have an increased risk of AMI, implying that some risk
modification is due to the absence of menstrual blood
losses and not to reduced estrogen production, and
(3) people from developing countries have less AMI
which, again, is in parallel to low body iron stores. Epide-
miological studies on the relationship between iron stores
and cardiovascular risk are still controversial. However,
evidence in favor of the iron hypothesis has become so
substantial that it cannot be ignored when the impact of
iron on human health is discussed.
Molecular Aspects
Iron participates in a complex pathophysiological
mechanism that is supposed to increase oxidative stress
and cardiovascular risk. Superoxide anions are produced
e.g. as a by-product of mitochondrial energy metabolism,
by xanthine oxidation or by neutrophils and macrophages
in inflamed tissues [33]. Such superoxide anions are trans-
formed by superoxide dismutase, by glutathione peroxi-
dase and catalase to H2O2 and finally to H2O which forms
a potent defense against oxidative stress (fig. 2). However,
superoxide anions can alternatively be converted to form
highly reactive hydroxyl radicals by iron mediated Fenton
chemistry (see Appendix) which potentiates local oxida-
tive stress, e.g. in mitochondria. Chelation of iron by
small endogenous ligands like citrate and ADP are no
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obstacle for the oscillation of iron between Fe2+ and Fe3+
which is the driving force of Fenton chemistry. One
hydroxyl radical can go through 10–15 reaction cycles and
destroy lipid membranes, proteins and cause DNA strand
breaks [34]. Thus, one hydroxyl radical will produce 10–
15 chain reaction seeds before it is stopped by radical
scavengers, e.g. ·-tocopherol, lycopene or ß-carotene,
which are consumed in the process and must be regener-
ated or replaced (fig. 2) [35].
Because of these mechanisms, the question of what
quantity of iron in the body is safe is closely related to the
question of which conditions disturb the equilibrium
between pro- and antioxidative mechanisms. In principle,
such disturbances can, firstly, be caused by an increased
basal generation rate of reactive oxygen species (ROS).
This is observed under pathological conditions, such as
inflammation and ischemia/reperfusion injury. Secondly,
local iron availability will aggravate oxidative stress of
any origin via Fenton chemistry. As excess iron cannot be
excreted from the body, it is either incorporated into
heme to serve specific functions or it is sequestered and
stored in ferritin. Hemeoxygenase 1 is induced in isch-
emia and liberates iron form heme [36]. Iron can also be
liberated from ferritin under oxidative stress [37]. In
addition, oxidative stress increases intracellular free iron
concentration via IRP activation (fig. 1), which promotes
the conversion of less reactive to more reactive radicals.
Thirdly, the cell may run out of radical scavengers due to
increased consumption under oxidative stress. In all 3
cases the equilibrium is shifted substantially to the proox-
idative side.
Free iron seems to play a crucial role in the amplifica-
tion of oxidative stress. The process is a self-amplifying
vicious circle. There is no place in the organims, neither in
ferritin nor in the heme-bound form, where excess iron
can be safely stored to prevent Fenton reaction from
occurring. A possible exception is hemoglobin-bound iron
in erythrocytes, because these cells have highly developed
intrinsic antioxidative defense mechanisms. Thus, excess
iron stores can be compared to a powder keg: it is not wise
to carry a higher supply than needed for necessary re-
quirements.
Iron-Promoted Oxidative Stress on the Organ Level
If these mechanistic considerations are valid, substitu-
tion or chelation of free iron should influence free radical
production in ischemia-reperfusion injury. On the organ
level, it should modulate lipid peroxidation and impair
organ function. Indeed, all these effects were observed in
corresponding animal experiments and clinical observa-
tions. The iron concentration in coronary flow fractions
increased with the duration of ischemia in isolated rat
hearts and cardiac contraction was impaired correspond-
ingly [38]. Also, administration of the iron chelator des-
ferrioxamine (DFO) before surgical occlusion of the cor-
onaries reduced the increment in free radical activity to
113% as compared to 136% in controls without DFO
[39]. Administration of DFO to dogs before coronary
occlusion impaired myocardial function to a lesser degree
than without DFO [40] and ventricular pressure in iso-
lated rabbit hearts was less attenuated [41]. Exocholine is
a new lipophilic iron chelator. It reduced hydroxyl radical
concentration and restored coronary flow rates and sys-
tolic pressure performance in isolated rabbit hearts after
coronary occlusion [42].
DFO administration before bypass operations in hu-
mans reduced the superoxide anion concentration in neu-
trophilic leukocytes, diminished mitochondrial swelling
and chemiluminescence for ROS in myocardial biospies
and lipid peroxidation. In experimental claudicatio inter-
mittens of rat hind limbs, parameters for lipid peroxida-
tion increased significantly less after DFO administration
[43] and carotid blood flow, cerebral O2 metabolism and
electrocortical activity were significantly less impaired in
experimental asphyxia of newborn lambs. A similar posi-
tive effect on the cerebrum was seen after allopurinol
administration which reduces xanthinoxidase and, thus,
ROS generation [44]. Administration of DFO before he-
patic ischemia as a model for the ischemic phase in liver
transplantation decreased lipid peroxidation and TNF·
release from Kupffer cells as well as morphological dam-
age [45, 46].
The above findings support a causal relationship be-
tween available free iron and the generation of free radi-
cals on the one hand and the extent of functional impair-
ment and morphological damage on the other. Unfortu-
nately, DFO has a comparably short half-life, penetrates
slowly across lipid membranes and depresses cardiovas-
cular function at high concentrations [47]. Therefore, the
usefulness of this chelator in the therapy of cardiovascular
diseases is limited. Still, to reduce free iron seems benefi-
cial in ischemia-reperfusion events, implying that high
iron stores are disadvantageous and may aggravate the
sequels of such events.
Epidemiological Studies on the Impact of Iron Status
on AMI Risk
Salonen et al. [48, 49] found a 2.2-fold increased risk of
AMI in Eastern Finnish males at serum ferritin levels of
1200 Ìg/l. An additional intake of 1 mg Fe/day was
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calculated to increase the cardiovascular risk by 5%.
These assumptions have been criticized insofar as the
impact of inflammatory diseases on serum ferritin should
have been controlled more rigidly and the relationship
between circulating ferritin and AMI risk should have
been pursued for the whole range of values. Besides, it was
argued that heterozygotes for hemochromatosis with their
slightly increased average iron stores should have an
increased cardiovascular risk as well, if a ferritin value of
1200 Ìg/l were to increase that risk. This had, indeed, not
been observed at that time; however, all of these require-
ments were fulfilled in the more recent studies on the sub-
ject as reported below.
No association was found between cardiovascular risk,
on the one hand, and serum iron concentrations, transfer-
rin saturation and total iron binding capacity (TIBC), on
the other hand, in two subsequent studies [50, 51]. A
transferrin saturation 160%, however, accompanied an
increased risk of AMI which fell short of statistical signifi-
cance [51]. Serum ferritin did not seem to be associated
with a cardiovascular risk in a study from Iceland [52],
although the risk was increased in people with low TIBC
representing high iron stores. Diets high in highly bio-
available heme iron increased the cardiovascular risk, but
went along with high fat and cholesterol intake as well
[53]. Morrison et al. [54] found a significantly increased
risk of AMI at serum iron concentrations of 1175 Ìg/dl,
which supports the iron hypothesis.
Most of these follow-up studies published between
1994 and 1997 did not support the findings of Salonen et
al. However, they raised concern about the choice of ade-
quate biomarkers to define body iron stores. Serum iron
concentrations and transferrin saturation represent no
advantage over ferritin concentration; on the contrary,
they are much more variable [55]. Other authors com-
plained about a confusing and inadequate design in some
of these studies, failure to exclude subjects with hepatic or
inflammatory diseases and inappropriate methods to de-
termine iron stores [56, 57]. There were calls for prospec-
tive studies using adequate parameters to define iron sta-
tus [55].
The most recent generation of studies tried to fill this
gap. Klipstein-Gobush et al. [58] found an 1.8-fold in-
creased risk of AMI at serum ferritin values of 1200 Ìg/l.
The risk increased 1.3-fold with every next tercile of
serum ferritin increments. A high intake of heme iron
increased the AMI risk 2.7-fold. Serum iron, transferrin
saturation and dietary iron intake did not correlate with
AMI risk, showing that these parameters are, indeed, less
appropriate than serum ferritin. Liver enzymes were con-
trolled to exclude hepatic damage. Inflammation was con-
trolled by determination of C-reactive protein and leuko-
cytes at the beginning of the study to rule out chronic
inflammatory diseases at that point in time. Acute dis-
eases that made the patient see a GP were registered by
the protocol and verified by research physicians. Erythro-
cyte sedimentation rates were determined to establish
whether earlier inflammatory processes had faded off
though they may have increased ferritin before. Alcohol
intake as confounding factor for serum ferritin increases
was accounted for. A Finnish study [59] used the ratio
between serum transferrin receptor concentration (TfR)
and serum ferritin which seems to represent the diagnos-
tic optimum to define body iron stores. TfR is largely
independent of inflammatory influences, decreases with
increasing iron stores and is most sensitive when iron
stores are low, while ferritin is more sensitive at high body
iron stores. If serum ferritin were high due to inflamma-
tion in spite of low iron stores, TfR would go up. There-
fore, parallel determination of both parameters reduces
the risk of misinterpreting high ferritin values due to
inflammation as an indicator of high iron stores. At ferri-
tin concentrations over 200 Ìg/l AMI risk was 2.5 times
higher and increased 2.0-fold with every next tercile of
ferritin increment. An additional dietary intake of 1 mg
Fe/day increased the AMI risk by 8.4%. Analyzing body
iron stones by terciles suggests a continuum of this param-
eter on the AMI risk. This is supported by a decreased
AMI risk in blood donors, who have low body iron stores
[60, 61]. The latter study controlled the health of donors
and nondonors alike to be comparable. Another trial
showed significantly higher serum ferritin values in coro-
nary artery disease patients with an early onset (age !46
years) as compared to others with a late onset (age 174
years) [62]. The most recent and best-controlled epidemi-
ological studies, thus, support the iron hypothesis of in-
creased cardiovascular risk. However, to finally prove the
causal association, an intervention trial would be needed;
this would be highly unethical in the light of the available
data.
AMI Risk in Heterozygotes of Hereditary
Hemochromatosis
Due to slightly increased iron absorption, 25–30% of
heterozygotes have elevated iron stores. The iron excess is
available early in life [63], which might increase cardio-
vascular risk. Indeed, there seems to be a family aggrega-
tion of hereditary cardiovascular risk in 5–7% of the male
population that cannot be explained by conventional risk
factors such as diabetes and hypertension [56]. In a pro-
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spective nested case control study in 11,631 subjects, 531
cardiovascular patients were compared to 535 controls
that died of other causes. Among the cardiovascular
deaths, 7.2% were heterozygous for hemochromatosis as
compared to 4.1% in controls. In controls, hypertension
and smoking increased cardiovascular risk by 2.2% as
compared to 40.0% in heterozygotes [64]. This risk incre-
ment should be due to extra iron, because this is what
characterizes the heterozyotes. The self-amplifying effect
of iron on ROS production described on the molecular
level is likely to be the responsible mechanism.
In a prospective cohort study in 1,150 Finnish males
6.7% were found to be heterozygous for hemochromatosis
[65]. 10.4% of heterozygotes had myocardial infarction as
compared to 5.6% in the control population. Again,
smoking increased the risk significantly. An increment in
serum ferritin of 100 Ìg/l increased the AMI risk by 52%.
These results take away one of the most severe objections
to the iron hypothesis of the cardiovascular risk, namely
that heterozygotes are not affected.
Iron Stores and Atherosclerosis
High iron concentrations were found in human athero-
sclerotic lesions [66]. Fe+ and Cu2+ increase local concen-
trations of hydroxyl radicals which are supposed to oxi-
dize surface structures of LDL. According to current
understanding this oxidation increases LDL affinity to
macrophage scavenger proteins and accelerates foam cell
formation in the vascular endothelium, which causes
cytotoxic endothelial injury via chemotactic mechanisms.
This process facilitates the entry of lipoproteins into the
intima, leading to smooth muscle cell proliferation and
the development of atherosclerotic plaques [57]. In agree-
ment with this concept, the iron content was higher in ath-
erosclerotic lesions in apolipoprotein-E-deficient mice. In
iron deficiency serum ferritin was reduced by one third
and the iron content in atherosclerotic lesions decreased
accordingly. This was paralleled by a reduction in number
and size of the lesions and reduced immunostaining for
epitopes of oxidized LDL [67]. Local Fenton chemistry in
the atherosclerotic plaques would also explain the lack of
an association between serum ferritin levels and measures
of LDL oxidation in human blood [68].
Sonographic assessment of carotid atherosclerosis was
correlated with iron stores in 847 persons aged between
40 and 79 years. Hypercholesterinemia increased the
lesions synergistically. The odd rate increased 1.5-fold
with each increment of 100 Ìg/l in serum ferritin [69]. In a
follow-up study, the risk of developing new atherosclerot-
ic lesions was correlated with body iron stores. Inflamma-
tion and cancer were excluded in these patients. Serum
iron and transferrin saturation were weak predictors. Pro-
gression of late atherosclerosis was not related to iron
stores [57].
Iron and Cancer
Molecular Mechanisms
Iron has been suggested to induce cancer by oxidative
damage of DNA. Renal adenocarcinoma induction in rats
[70] after intraperitoneal injection of Fe-nitrilotriacetic
acid (Fe-NTA) supports this notion. In contrast to intra-
peritoneally applied ferric succhrate, which is insoluble
and induces local peritoneal mesothelioma [71], soluble
Fe-NTA is absorbed by the peritoneum and circulates in
the blood. After glomerular filtration iron finds an opti-
mal environment for the Fenton reaction in the lumen of
the proximal renal tubules. At this location, lipid peroxi-
dation turned out to be clearly associated with the induc-
tion of renal cancer [72]; both could be significantly
reduced by vitamin E administration [73]. Chelated Fe3+
effectively catalyzed DNA single and double strand
breaks producing 8-OHGua as a maker for oxidative
DNA damage [74] and interstrand cross-links by site-spe-
cific mechanisms [34]. Induction of lung cancer after
asbestos inhalation relates to the iron content of different
asbestos fibers [75] and iron and nitric oxide seem to be
necessary for the mutagenic action of asbestos fibers [76].
Moreover, a high iron supply supports tumor cell prolifer-
ation [77]. Ample iron supply is likely to promote tumor
growth whereas iron restriction can reduce cancer induc-
tion [78]. As a defense against iron-induced oxidative
stress human tumor cells produce glutathione S-transfer-
ase pi. These mechanisms explain promoting effects of
iron on dimethylnitrosamine- and dimethylbenz(a)an-
thracene-induced tumors in animal experiments [79]. Ox-
idative stress, moreover, may accelerate the conversion of
precarcinogens to carcinogens [80].
Epidemiological Observations
Stevens et al. [81] first reported an association between
iron stores and cancer; this was criticized because of the
small differences in transferrin saturation (+2.4%) and
TIBC (–1.5%) between cancer and noncancer groups.
Also, the risk of cancer induction was not stratified
according to different periods of follow-up duration. It
was suspected that these iron status indicators have been
increased as a consequence of cancer that was present at
the start of the study [82]. This objection was overcome by
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longer follow-up periods, after which the correlation be-
tween high iron stores and cancer was still present [83]. In
addition, a dose-response relationship between transfer-
rin saturation and relative risk of cancer was derived. The
risk increased progressively at transferrin saturation lev-
els above 40%. The cancer frequency in esophagus, blad-
der and in the colorectal area increased in parallel to iron
stores. Dietary phytates, themselves known to decrease
iron availability, seem to protect the colon from lipid
peroxidation, which is in agreement with these observa-
tions [84]. In contrast, the frequency of stomach cancer
decreased with iron status, because induction of this
tumor is frequently associated with low gastric acidity
leading to low iron absorption [83]. Knekt et al. [85]
found the risk of colorectal and lung cancer to be related
with increased iron stores. Again, differences in iron sta-
tus between cancer and noncancer groups were small. The
role of iron in cancer promotion is supported by the thera-
peutic effect of iron chelators in the therapy of neuroblas-
toma [86] and by reports on a reduced cancer risk in blood
donors [87].
Promotion of tumor growth after iron supplementa-
tion in animals seems a very reproducible finding. A cau-
sal relationship between cancer promotion, possibly also
between cancer induction and iron stores, is likely but not
firmly proven for humans. On this database, an interven-
tion trial in humans to prove or disqualify this issue
would be clearly unethical and iron supplementation
beyond the RDA requirements cannot be recommended.
Safety of Iron in Food
Food safety tries to avoid deficiency states as well as
the risks of excess intake; additional aspects of food safe-
ty, like allergy, microbial or toxic contamination and the
impact of food additives or agrochemicals shall not be dis-
cussed here, although cadmium, lead, nickel, cobalt and
plutonium may accumulate in the body to a greater extent
in iron deficiency, as these metals partly share the absorp-
tive pathways of iron which is negatively correlated with
iron stores [88]. However, there is no regulated iron excre-
tion in situations of dietary overload. To avoid adverse
effects, therefore, iron intake should not exceed these met-
abolic requirements. Excess intake of pharmaceutical iron
preparations may lead to acute toxicity and secondary
hemochromatosis. At therapeutic dose levels they cause
side effects. This is of limited relevance to assess the risk
of dieteary iron, though it helps to characterize possible
hazards. Chronic excess intake of highly available iron
with a food item was observed in Bantu siderosis, where
chronic intakes between 50 and 100 mg Fe/day caused
live cirrhosis, diabetes and heart failure. Applying a safety
factor of 2 would lead to an USL of 25–50 mg Fe/day for
conventional iron toxicity as an endpoint.
However, reports on an association between iron stores
and cardiovascular and cancer risk urge to extend the
database for risk assessment. The molecule mechanisms
of how iron accumulates in specific tissues under oxida-
tive stress and amplifies it are known. In this perspective
the question of how much iron is safe needs to be re-
phrased. We should ask to what extent we can rely on
antioxidative mechanisms to prevent cardiovascular dis-
eases and cancer as sequels of iron-amplified oxidative
stress. In healthy humans, the answer is stochastic; in the
vast majority of cases, antioxidative defense is sufficient.
However, high iron stores seem to shift the odds for the
worse as is suggested by the more recent, intensely con-
trolled epidemiological studies [58, 59, 64, 65]. Looking at
animal experiments and clinical data, the balance be-
tween oxidative stress and antioxidative defense seems
clearly disturbed in ischemia-reperfusion damage. There
is profound evidence that iron-amplified oxidative stress
participates in the pathophysiology of AMI, stroke and
cancer, which are the most common causes of death in the
industrialized countries. Even though the issut is not
finally settled, available data do suggest that the UL
should not be set beyond the RDA, i.e. not beyond the
requirement of growth and metabolic demand. These,
however, must be met to avoid deficiency symptoms. The
same rationale applies for pharmaceutical iron substitu-
tion under medical supervision, e.g. to replete iron losses
after bleeding.
Appendix
Fe2+ + H2O2 → Fe3+ + OH– + HOW
O2–W + Fe3+ → O2 + Fe2+
O2–W + H2O2 → O2 + OH– + HOW
Superoxide may dismutate to form hydrogen peroxide and the
hydroxyl radical (HOW) by Fenton and Haber-Weiss chemistry. This
process is catalyzed by iron which oscillates between its divalent and
its trivalent form. The hydroxyl radical is an extremely potent oxidiz-
ing species which can depolymerize polysaccharides, cause DNA
strand breaks, inactivate enzymes and initiate lipid peroxidation
[35].
100 Ann Nutr Metab 2001;45:91–101 Schümann
References
1 Hathcock JN: Safety limits of nutrition. J Nutr
1996;126:2386S–2389S.
2 Hallberg L, Rossander L: Improvement of nu-
trition in developing countries: Comparison of
adding meat, soy protein, ascorbic acid, citric
acid and ferrous sulfate on iron absorption
from a simple Latin American meal. Am J Clin
Nutr 1984;39:578–583.
3 Monsen ER, Hallberg L, Layrisse M, Hegsted
M, Cook JD, Merz W, Finch CA: Estimation of
available dietary iron. Am J Clin Nutr 1978;31:
134–141.
4 Dewey KG, Romero-Abal ME, Quan de Serra-
no J, Bulux J, Peerson JM, Engle P, Solomons
NW: Effects of discontinuing coffee intake on
iron status of iron-deficient Guatemalan tod-
dlers: A randomized intervention study. Am J
Clin Nutr 1997;66:168–176.
5 Lozoff B, Jemenez E, Wolf AW: Long-term
developmental outcome of infants with iron-
deficiency. N Engl J Med 1991;325:687–694.
6 Baynes RD, Bothwell TH: Iron deficiency.
Annu Rev Nutr 1990;10:133–148.
7 Lynch SR: Iron; in Solomons NW, Rosenberg
ICH (eds): Absorption and Malabsorption of
Mineral Nutrients. New York, Liss, 1984, pp
89–124.
8 Gunshin H, Mackenzie B, Berger U, Gunshin
Y, Romero MF, Boron WF, Nussberger S, Gal-
lan JL, Hediger MA: Cloning and characteriza-
tion of a mammalian proton-coupled metal-ion
transporter. Nature 1997;388:482–488.
9 Schümann K, Moret R, Künzle H, Kühn LC:
Iron regulatory protein as an endogenous sen-
sor of iron in rat intetinal mucosa. Possible
implications for the regulation of iron absorp-
tion. Eur J Biochem 1999;260:362–372.
10 Oates PS, Trinder D, Morgan EH: Gastrointes-
tinal function, divalent metal transporter-1 ex-
pression and intestinal iron absorption. Pflü-
gers Arch 2000;440:496–502.
11 Mckie AT, Marciani P, Rolfs A, Brennan K,
Wehr K, Barrow D, Miret S, Bomford A, Peters
TJ, Farzaneh F, Hediger MA, Hentze MW,
Simpson RJ: A novel duodenal iron-regulated
transporter, IREG1, implicated in the baso-
lateral transfer of iron to the circulation. Mol
Cell 2000;5:299–309.
12 Wyllie JC, Kaufmann N: An electron micro-
scopic study of heme uptake by rat duodenum.
Lab Invest 1982;47:471–476.
13 Raffin SB, Woo CH, Roost KT, Price DC,
Schmid R: Intestinal absorption of hemoglobin
iron-heme clevage by mucosal heme oxy-
genase. J Clin Invest 1974;54:1344–1352.
14 Roberts ST, Henderson RW, Young GP: Mod-
ulation of uptake of heme by rat small intesti-
nal mucosa in iron deficiency. Am J Physiol
1993;265:G712–G718.
15 Hallberg L, Hulten L, Gramatkovski E: Iron
absorption from the whole diet in men: How
effective is the regulation of iron asborption.
Am J Clin Nutr 1997;66:347–356.
16 Barrett JFR, Whittaker PG, Williams JG, Lind
T: Absorption of non-haem iron from food dur-
ing normal pregnancy. Br Med J 1994;309:79–
82.
17 Beutler E: How little we know about the ab-
sorption of iron. Am J Clin Nutr 1997;66:419–
420.
18 Hallberg L: Oral iron therapy – factors affect-
ing the absorption; in Hallberg L, Harwerth
HG, Vanotti A (eds): Iron Deficiency. New
York, Academic Press, 1970, pp 551–561.
19 Cook JD, Reddy MB: Efficacy of weekly com-
pared with daily iron supplementation. Am J
Clin Nutr 1996;62:117–120.
20 Pizzaro F, Olivares M, Arredondo M, Her-
trampf E, Walter T: Does Daily Iron Adminis-
tration Produce a Mucosal Blockade? Wage-
ningen, European Academy of Nutritional
Science, 1997.
21 Powell LW, Jazwinska E, Halliday JW: Prima-
ry iron overload; in Brock JH, Halliday JW,
Pippard MJ, Powell LW (eds): Iron Metabo-
lism in Health and Disease. London, Saunders,
1994, pp 227–270.
22 Solomons NW: Competitive interaction of iron
and zinc in the diet. Consequences for human
nutrition. J Nutr 1986;110:927–934.
23 Klausner RD, Rouault TA, Harford JB: Regu-
lation of the fate of mRNA: The control of cel-
lular iron metabolism. Cell 1993;72:19–28.
24 Hentze MW, Kühn LC: Molecular control of
vertebrate iron metabolism – mRNA-based
regulatory circuits operated by iron, nitric ox-
ide, and oxidative stress. Proc Natl Acad Sci
USA 1996;93:8175–8182.
25 Berkovitch M, Matsui D, Lamm SH, Rosa F,
Koren G: Recent increases in numbers and risk
of fatalities in young children ingesting iron
preparations. Vet Hum Toxicol 1994;36:53–
55.
26 Ellenhorn MJ, Barceloux DG (eds): Iron. Medi-
cal Toxicology. New York, Elsevier, 1988, pp
1023–1030.
27 Ganzoni AM, Töndung G, Rhymer K: Orale
Eisenmedikation. Dtsch Med Wochenschr
1974;99:1175–1178.
28 Reddajah VP, Prasanna P, Ramachandran K,
Nath LM, Sood SU, Madan N, Rusia U: Sup-
plementary iron dose in pregnant anemia pro-
phylaxis. Indian J Pediatr 1989;65:109–114.
29 Green P, Evitan JM, Sivota P, Avidor I: Sec-
ondary hemochromatosis due to prolonged
iron ingestion. Isr J Med Sci 1989;25:199–201.
30 Bothwell TH, Seftel H, Jacob P, Torrance JD,
Baumslag N: Iron overload in Bantu subjects.
Am J Clin Nutr 1964;14:47–51.
31 Gordeuk U, Mukiibi J, Hasstedt SJ: Iron over-
load in Africa. Interaction between a gene and
dietary iron control. N Engl J Med 1992;326:
95–100.
32 Sullivan JL: Iron versus cholesterol – Perspec-
tives on the iron and heart debate. J Clin Epi-
demiol 1996;49:1345–1352.
33 Rosenthal GJ, Germolec DR, Blazka ME, Cor-
sini E, Simenova P, Pollock P, Kong L-Y,
Kwon J, Luster MI: Asbestos stimulates IL-8
production from human lung epithelial cells. J
Immunol 1994;153:3237–3244.
34 Lloyd DR, Phillips DH: Oxidative DNA dam-
age mediated by copper (II), iron (II) and nickel
(II) Fenton reactions: Evidence for site specific
mechanisms in the formation of double-strand
breaks, 8-hydroxyguanosine and putative in-
strand cross-links. Mutat Res 1999;424:23–36.
35 McCord JM: Iron, free radicals, and oxidative
injury. Semin Hematol 1998;35:5–12.
36 Koishinako J, Miettinen S, Keinänen R, Var-
tieinen N, Roivainen R, Laitinen JT: Long-
term induction of haem oxygenase-1 (HSP-32)
in astrocytes and microglia following transient
focal brain ischemia in the rat. Eur J Neurosci
1996;8:2265–2272.
37 Biemond P, Eijk HGN, Swaak AJG, Koster JF:
Iron mobilization from ferritin by superoxide
derived from stimulated PMN leukocytes. J
Clin Invest 1984;73:1576–1579.
38 Berenshtein E, Mayer B, Goldberg C, Kitrossky
N, Chevion M: Patterns of metabolization of
copper and iron following myocardial isch-
emia: Possible predictive criteria for tissue in-
jury. J Mol Cell Cardiol 1997;29:3025–3034.
39 Spencer KT, Lindower PD, Buettner GR, Ker-
ber RE: Transition metal chelators reduce di-
rectly measured myocardial free radical pro-
duction during reperfusion. J Cardiovasc Phar-
macol 1998;32:343–348.
40 Bolli R, Patel BS, Zhu W: The iron chelator
desferrioxamine attenuates postischemic ven-
tricular dysfunction. Am J Physiol 1987;253:
H1372–H1380.
41 Williams RE, Zweier JL, Flaherty JT: Treat-
ment with deferoxamine during ischemia im-
proves functional and metabolic recovery and
reduces reperfusion-induced oxygen radical
generation in rabbit hearts. Circulation 1991;
83:1006–1014.
42 Horwitz LD, Sherman NA, Kong Y, Pike AW,
Gobin J, Fennessey PV, Horwitz MA: Lipo-
philic siderophores of Mycobacterium tubercu-
losis prevent cardiac reperfusion injury. Proc
Natl Acad Sci USA 1998;95:5263–5268.
43 Fantini GA, Yoshioka T: Desferoxamine pre-
vents lipid peroxidation and attenuates reoxy-
genation injury in postischemic skeletal mus-
cle. Am J Physiol 1993;264:H1953–H1959.
44 Shadid M, Moison R, Steendijk P, Hiltermann
L, Berger HM, van Bel F: The effect of antioxi-
dative combination therapy on posthypoxic-
ischemic perfusion, metabolism, and electrical
activity of the newborn brain. Pediatr Res
1998;44:119–124.
45 Colletti LM, Remick DG, Campbell DA: Des-
feral attenuates TNF release following hepatic
ischemia/reperfusion. J Surg Res 1994;57:447–
453.
Safety Aspects of Iron in Food Ann Nutr Metab 2001;45:91–101 101
46 Van Jaarsveld H, Kuyl JM, Wild NM: Isch-
emia/reperfusion injury is aggravated by an
iron supplemented diet and is partly prevented
by simultaneous antioxidant supplementation.
Res Commun Mol Pathol Pharmacol 1994;86:
273–285.
47 Arora SA, Gores GJ: The role of metals in isch-
emia/reperfusion injury of the liver. Semin Liv-
er Dis 1996;16:31–38.
48 Salonen JT, Nyyssönen K, Korpela H, Tuomi-
lehto J, Seppänen R, Salonen R: High stored
iron levels are associated with excess risk of
myocardial infarction in eastern Finnish men.
Circulation 1992;86:803–811.
49 Salonen JT, Nyyssönen K, Salonen R: Body
iron stores and risk of coronary heart disease
(letter). N Engl J Med 1994;334:1159.
50 Sempos CT, Looker AG, Gillum RF, Makug
DM: Body iron stores and the risk of coronary
heart disease. N Engl J Med 1994;330:1119–
1124.
51 Baer DM, Takawa IS, Hurley LB: Iron stores
are not associated with acute myocardial in-
farction. Circulation 1994;89:2915–2918.
52 Magnusson M, Sigufsson N, Sigvaldason H,
Johannesson M, Magnusson S, Thorgeirsson
G: Low iron-binding capacity as a risk factor
for myocardial infarction. Circulation 1994;89:
102–108.
53 Ascherio A, Willett WC, Rimm EB, Giovan-
nucci EL, Stampfer MJ: Dietary iron intake
and risk of coronary disease among men. Cir-
culation 1994;89:969–974.
54 Morrison HI, Semenciw RM, Mao Y, Wigle
DT: Serum iron and fatal myocardial infarc-
tion. Epidemiology 1994;5:243–246.
55 Sempos CT, Looker AC, Gillum RF: Iron and
heart disease: The epidemiological data. Nutr
Rev 1996;54:73–84.
56 Sullivan JL: Iron and the genetics of cardio-
vascular disease. Circulation 1999;100:1260–
1263.
57 Kiechl S, Willeit J, Egger G, Poewe W, Ober-
hollenzer F: Body iron stores and the risk of
carotid atherosclerosis. Circulation 1997;96:
3300–3307.
58 Klipstein-Gobusch K, Koster JF, Grobbee DE,
Lindemans J, Boeing H, Hofman A, Witteman
JCM: Serum ferritin and risk of myocardial
infarction in the elderly: The Rotterdam study.
Am J Clin Nutr 1999;69:1231–1236.
59 Tuomainen T-P, Punnonen K, Nyyssönen K,
Salonen JT: Association between body iron
stores and the risk of acute myocardial infarc-
tion in men. Circulation 1998;97:1461–1466.
60 Salonen JT, Tuomainen T-P, Salonen R, Lakka
TA, Myyssönen K: Donation of blood as asso-
ciated with reduced risk of myocardial infarc-
tion. Am J Epidemiol 1998;148:445–451.
61 Meyers DG, Stickland D, Molsley PA, Seburg
JJ, Wilson JE, Mc Manu BF: Possible associa-
tion of a reduction in cardiovascular events
with blood donation. Heart 1997;78:188–193.
62 Nassar BA, Zayed EM, Title LM, O’Neill BJ,
Bata IR, Kirkland SA, Dunn J, Dempsey GI,
Toon M-H, Johnstone DE: Relation of HFE
gene mutations, high iron stores and early onset
coronary artery disease. Can J Cardiol 1998;14:
215–220.
63 Bulaj ZJ, Griffen LM, Jorde LB, Edwards CQ,
Kushner JP: Clinical and biochemical abnor-
malities in people heterozygous for hemochro-
matosis. N Engl J Med 1996;335:1799–1805.
64 Roest M, van der Schouw YT, de Valk B, Marx
JJM, Tempelman MJ, de Groot PG, Sixma JJ,
Banga JD: Heterozygosity for a hereditary he-
mochromatosis gene is associated with cardio-
vascular mortality in women. Circulation
1999;100:1268–1273.
65 Tuomainen T-P, Kontula K, Nyyssönen K,
Lakka TA, Heliö T, Salonen JT: Increased risk
of acute myocardial infarction in carriers of the
hemochromatosis gene Cys282Tyr mutation.
Circulation 1999;100:1274–1279.
66 Swain J, Gutteridge JM: Prooxidant iron and
copper, with ferroxidase and xanthine oxidase
activities in human atherosclerotic material.
FEBS Lett 1995;368:513–515.
67 Lee T-S, Shiao M-S, Pan C-C, Chau L-Y: Iron-
deficient diet reduces atherosclerotic lesion
in apoE-deficient mice. Circulation 1999;99:
1222–1229.
68 Iribarren C, Sempos CT, Eckfeldt JH, Folson
AR: Lack of association between ferritin level
and measures of LDL oxidation: The ARIC
study. Atherosclerosis 1998;139:189–195.
69 Kiechl S, Aichner F, Gerstenbrand F, Egger G,
Mair A, Rungger G, Spögler F, Jarosch E,
Oberhollenzer F, Willeit J: Body iron stores
and presence of carotid atherosclerosis. Arte-
rioscler Thromb 1994;14:1625–1630.
70 Okada S, Midorikawa O: Induction of rat renal
adenocarcinoma by Fe-nitrilotriacetate (Fe-
NTA). Jpn Arch Intern Med 1982;29:385–
491.
71 Okada S, Hamazaki S, Toyokuni S, Midorika-
wa O: Induction of mesothelioma by intraperi-
toneal injections of ferric succhrate in male
Wistar rats. Br J Cancer 1989;60:708–711.
72 Toyokuni S, Uchida K, Okamoto K, Hattori Y,
Nakakuki Y, Hiai H, Stadtman ER: Formation
of 4-hydroxy-2-nonenal-modified proteins in
the renal proximal tubules of rats treated with a
renal carcinogen ferric nitrilotriacetate. Proc
Soc Acad Sci USA 1994;91:2616–2620.
73 Zhang D, Okada S, Yu Y, Pingdong Z, Yama-
guchi R, Kasai H: Vitamin E inhibits apopto-
sis, DNA modification, and cancer induced by
iron-mediated peroxidation in Wistar rat kid-
ney. Cancer Res 1997;57:2410–2414.
74 Loft S, Vistisen K, Ewertz M, Tjonneland A,
Overvad K, Poulsen HE: Oxidative DNA dam-
age estimated by 8-hydroxy-deoxyguanosine
excretion in humans: Influence of smoking,
gender and body mass index. Carcinogenesis
1992;13:2241–2247.
75 Mossman BT, Bignon J, Corn M, Seaton A,
Gee JBL: Asbestosis: Scientific developments
and implications for public policy. Science
1990;247:294–301.
76 Park SH, Aust AE: Participation of iron and
nitric oxide in the mutagenicity of asbestos in
hpgrt–, gpt+ Chinese hamster V79 cells. Can-
cer Res 1998;58:1144–1148.
77 Bergeron RJ, Streiff RR, Elliott GT: Influence
of iron on in vitro proliferation and lethality of
L1210 cells. J Nutr 1985;115:369–374.
78 Thompson HJ, Kennedy K, Witt M, Juzefky J:
Effect of dietary iron deficiency or excess on
the induction of mammary carcinogenesis by
1-methyl-1-nitrourea. Carcinogenesis 1991;12:
111–114.
79 Diwan BA, Kasprzak KS, Anderson LM: Pro-
motion of dimethylbenz(a)anthracene-initiat-
ed mammary carcinogenesis by iron in female
Sprague-Dawley rats. Carcinogenesis 1997;18:
1757–1762.
80 Babbs CF: Free radicals and the etiology of
colon cancer. Free Radic Biol Med 1990;8:
191–200.
81 Stevens RG, Jones Y, Micozzi MS, Taylor RR:
Body iron stores and the risk of cancer. N Engl
J Med 1988;319:1047–1052.
82 Yip R, Williamson DF: Body iron stores and
the risk of cancer (letter). N Engl J Med 1989;
320:1012.
83 Stevens RG, Graubard BI, Micozzi MS, Nerii-
shi K, Blumberg BS: Moderate elevation of
body iron level and increased risk of cancer
occurrence and death. Int J Cancer 1994;56:
364–369.
84 Porres JM, Stahl CH, Cheng WH, Fu Y, Ro-
neker KR, Pond WG, Lei XG: Dietary intrin-
sic phytate protects colon from lipid peroxida-
tion in pigs with a moderately high iron intake.
Proc Soc Exp Biol Med 1999;221:80–86.
85 Knekt P, Reunanen A, Takkunen H, Aromaa
A, Heliövaara M, Hakulinen T: Body iron
stores and risk of cancer. Int J Cancer 1994;56:
379–382.
86 Donfrancesco A, Deb G, DeSio L, Cozza R,
Castellano A: Role of deferoxamine in tumor
therapy. Acta Haematol 1996;95:66–69.
87 Merk K, Mattsson B, Mattsson A, Holm A,
Gullbring G, Björgholm B: The incidence of
cancer among blood donors. Int J Epidemiol
1990;19:505–509.
88 Elsenhans B, Schümann K, Forth W: Toxic
metals: Interactions with essential metals; in
Rowland IR (ed): Nutrition, Toxicity, and Can-
cer. Boca Raton, CRC Press, 1991, chap 8, pp
223–258.
89 Pantopoulos K, Hentze MW: Regulation of
iron metabolism in higher eukaryotes: Iron-sul-
fur centers as genetic switches; in Ferreira GC,
Moura JJG, France R (eds): Iron Metabolism.
Weinheim, Wiley, 1999, pp 131–152.
